QR-kod

SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients—A Single-Center Experience

Immunocompromised patients experience reduced vaccine effectiveness and are at higher risk for coronavirus disease 19 (COVID-19) death. Pre-exposure prophylaxis (PrEP) aims to protect these patients. So far, only tixagevimab/cilgavimab is authorized for use as PrEP. This paper aims to provide real-w...

Full beskrivning

Sparad:
Huvudupphov: David Totschnig, Max Augustin, Iulia Niculescu, Hermann Laferl, Sonja Jansen-Skoupy, Clara Lehmann, Christoph Wenisch, Alexander Zoufaly
Materialtyp: Artigo
Språk:Inglês
Utgiven: MDPI AG 2022-10-01
Serie:Viruses
Ämnen:
SARS-CoV-2 PrEP
pre-exposure prophylaxis
immunocompromised patients
sotrovimab
tixagevimab/cilgavimab
Länkar:https://www.mdpi.com/1999-4915/14/10/2278
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk